Christin Tse

Abbott Fund — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index5.8kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell death mechanisms and regulation(16), Cancer therapeutics and mechanisms(14), Peptidase Inhibition and Analysis(12), Lung Cancer Research Studies(11), Genomics and Chromatin Dynamics(9)

Publications46 total

Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
2023Open Access
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
2023Open Access
Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
2023Open Access
Data from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
2023Open Access
Data from Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
2023Open Access
Data from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2023Open Access
Data from Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
2023Open Access
Supplementary Tables 1-2 from Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
2023Open Access
Data from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2023Open Access
Supplementary Methods, Figures 1-7, Tables 1-2 from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2023Open Access
Supplementary Methods, Figures 1-7, Tables 1-2 from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2023Open Access
Supplementary Tables 1-2 from Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Saul H. Rosenberg(30), Stephen W. Fesik(24), Steven W. Elmore(22), Michael J. Mitten(18), Stephen K. Tahir(18), Haichao Zhang(13), Anatol Oleksijew(13), David J. Frost(13), Mark G. Anderson(12), Joy Bauch(12), Alex R. Shoemaker(12), Scott Ackler(12), Marion Refici(11), Baole Wang(11), Steve W. Elmore(10), Paul Nimmer(9), Sally Schlessinger(9), Sanjay R. Chemburkar(9), Jessica Adickes(8), Jeffrey C. Hansen(8)